Over the past decade, the use of β-blockers has transformed the management and prognosis of patients with heart failure (HF). A post hoc analysis of the SENIORS study now raises questions about the validity of a composite 'ischemic' end point that includes sudden death in trials of β-blocker therapy for patients with HF.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
[No authors listed] A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247, 1707–1714 (1982).
[No authors listed] Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304, 801–807 (1981).
Ambrosio, G. et al. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 97, 209–214 (2011).
[No authors listed] The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9–13 (1999).
Packer, M. et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651–1658 (2001).
Hjalmarson, A. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295–1302 (2000).
Bardy, G. H. et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225–237 (2005).
Kjekshus, J. et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248–2261 (2007).
Tavazzi, L. et al. for the Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231–1239 (2008).
Bethel, M. A. et al. Determining the most appropriate components for a composite clinical trial outcome. Am. Heart J. 156, 633–640 (2008).
Acknowledgements
J. J. V. McMurray is currently supported by the Eugene Braunwald Endowment for the Advancement of Cardiovascular Discovery and Care at the Brigham and Women's Hospital, Boston, MA, USA.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
McMurray, J. Acute ischemic events in HF—should we include sudden death?. Nat Rev Cardiol 8, 192–193 (2011). https://doi.org/10.1038/nrcardio.2011.22
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.22
